ABB · Mega Cap · NYSE · Healthcare · Drug Manufacturers - General
Free research brief
Free to track. No card required.
Price, momentum, and the numbers behind the story.
Overall score
60/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Where the analysts and the crowd stand, and what it's worth to know first.
Lowest
$83
Median target
$90
Highest
$105
Current price
$256.42
What it earns and where it earns it, what you're paying for the stock, and the risk sitting on the balance sheet.
Forward P/E
Favorable · 17% below avg
27.58x
ROIC
Strong · Excellent capital returns
25.1%
ROE
Favorable · 15221.8% - strong capital efficiency
32.6%
Debt / equity
Favorable · 0.56 - strong leverage
0.56x
Price / FCF
Rich · Expensive vs. cash flow
35.78x
EV / EBITDA
Rich · Earnings can't support price
23.85x
ABB against the names it's actually compared to.
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $465.76B | 128.6 | +18.6% | 60 | |
| $10.51B | 20.0 | +19.7% | 78 | |
| $33.17B | 34.7 | +15.5% | 78 | |
| $4.12B | 12.4 | +13.5% | 78 | |
| $1.08T | 39.1 | +49.6% | 77 |